Description: The actuarial profession is changing rapidly and the skills needed to be successful are also changing. In this session, we will debate key topics and questions, such as: What is the predominant future career path for actuaries? Specialists or generalists? Does the actuarial profession have a meaningful value prop outside our core domains e.g. insurance? What skills are needed for the actuary of the future? What’s the best approach to improve actuarial storytelling to non-actuarial audiences? What’s the role of actuaries to managing and predicting emerging trends and assumptions? What is the role of actuaries in relation to development and ownership of advanced modeling? Is the future actuarial profession smaller/larger than it is today? In either case, how does it differ from today in terms of make-up, deployment, function, purpose, value add, etc.?

Description: Creating a predictive model is one thing, but then taking that model and getting full stakeholder buy-in is another. Learn from presenters' experiences and insights on proving model effectiveness in the long-term care (LTC), life and annuity spaces. Explore various topics such as feasibility, model transparency, fairness and equity, ROI measurement, data assets and compliance, infrastructure and more. By the end of the session, you will gain an understanding of how to navigate the challenges of proving the effectiveness of predictive modeling and obtaining management buy-in.

Description: Hear about the new hope biosimilars bring in helping payers and patients manage the rapidly growing pharmacy spend. The Big Event, encompassing multiple Humira biosimilars, launches in 2023 and could set the tone for how much biosimilars can be expected to contribute to solving our pharmacy spend challenges. What will be the financial impact of the Big Event and this coming wave? What can be done to maximize adoption of biosimilars? What strategies are available to maximize savings for payers and patients?

Description: High inflation rates can affect disability insurance in a variety of ways. Learn about rising price and wage inflation trends and why they are of interest to disability insurers. You will also hear presenters address topics such as recessionary pressures, the eroding value of benefits, wage growth, top-line trends and expense pressures. By attending the session, you will gain insight into how inflation should be considered in pricing, reserving and financial modeling.

Description: As our industry rapidly adopts more advanced technologies, today's actuaries have more data and greater analytical capabilities than ever before. Nevertheless, these advancements come with their own set of challenges.Come explore the tools and techniques to optimize your processes and avoid common pitfalls so that you can get the most out of your experience studies.

Description: Come hear about the latest trends and insights as this panel discusses the happenings in life insurance marketplace. The panel plans to cover product, regulatory, underwriting, marketing, and other trends to help keep the audience up to date on many of Life's changing events.

Description: Actuaries historically modeled new launches in pharmaceuticals by anticipating the expected change to the market basket. This became more complicated with the recent launches of gene and cell therapies as they address rare diseases. Rare conditions have low total member volume to study and some do not currently have a diagnosis code to identify them within claims data. Addressing this modeling challenge has been growing more important in the recent years with the number of therapies launching. What has the health care industry, and more specifically health care, done to enhance modeling and how should this be altered for the future? Additionally, historic modeling has sometimes incorporated a level of direct medical treatment cost offsets where studies have shown lower treatment costs are achievable. Can gene and cell financial modeling include cost offsets as well? And if so, what are suggested precautions or limitations to this effort?

Description: Renal disease is a very heterogenous medical condition whose end state is dialysis, a recurring cost intensive medical condition. Dialysis cost is one of the major medical cost drivers in USA. Insufficient and improper care management in the early stages of CKD (chronic kidney disease) leads to early incidence of end stage renal disease (ESRD) among CKD patients which not only leads to high medical costs, but also reflects poor health quality.

Description: Learn through examples how actuaries working in traditional and nontraditional actuarial roles should apply ASOPs when navigating through situational challenges when collaborating with other professionals. Examples of these professionals include regulators, accounting, management, marketing, underwriting as well as when providing advisory services to external clients.

Description: Discover a comparison of U.S. and international mandated leave programs which mandate employers to provide a minimum level of benefits to employees for qualifying leaves of absence, such as parental leave or medical leave.